Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan

Inclusion Criteria: * Aged 4 to 6 years inclusive on the day of inclusion * Subjects who received 4 times an IPV-containing vaccine (DTaP-IPV or IPV) during first (3 doses) and second year of life (one dose) * Informed consent form signed by the parent(s) or other legal representative * Able to attend all scheduled visits and to comply with all trial procedures. Exclusion Criteria: * Fever ≥ 37.5°C (axillary temperature) on the day of inclusion * Any serious disease whether acute or chronic * Past or current medical history of Guillain-Barre syndrome, acute thrombocytopenic purpura or encephalopathy * History of poliomyelitis infection * History of a life threatening reaction to a vaccine containing the same substances of the study vaccine * History of anaphylaxis or allergy to any of the study vaccine components * Congenital or current/previous acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy * Participation in another clinical trial within 6 months before the trial inclusion * Planned participation in another clinical trial during the present trial period * Received oral or injected antibiotic therapy within the 72 hours prior to any blood draw * Received antipyretics/analgesics/Non-steroidal anti-inflammatory drugs (considered as a single category) within 4 hours prior to vaccination * Blood or blood-derived products received in the past or current or planned administration during the trial (including immunoglobulins) * Any vaccination with live vaccines within the past 27 days preceding the trial vaccination * Any vaccination with inactivated vaccines within the past 6 days preceding the trial vaccination * Clinical or known serological evidence of systemic illness including Hepatitis B, Hepatitis C and/or HIV infection * Subject ineligible according to the Investigator's clinical judgment.